Checking the mobility of a promising vision impairment therapeutic

Globally, over 2 billion people suffer from vision impairment. Deglycating enzyme fructosamine-3-kinase (FN3K) was recently proposed as a potential therapeutic, but for further biopharmaceutical development, knowledge on its manufacturability and stability and mobility in the vitreous fluid of the eye is indispensable. Fluorescence correlation spectroscopy was used to study protein mobility in non-sonicated bovine vitreous, human vitreous, and intact bovine eyes.

Read more:

Minnaert, A. K., van Schie, L., Grootaert, H., Himpe, J., Devos, S., Weyts, W., De Keersmaecker, H., Braeckmans, K., Van Aken, E., Delanghe, J. R., De Smedt, S. C., Callewaert, N., & Remaut, K. (2022). Yeast-produced fructosamine-3-kinase retains mobility after ex vivo intravitreal injection in human and bovine eyes as determined by Fluorescence Correlation Spectroscopy. International journal of pharmaceutics, 621, 121772.

https://doi.org/10.1016/j.ijpharm.2022.121772